B7-H4 expression by nonhematopoietic cells in the tumor microenvironment promotes antitumor immunity

Cancer Immunology Research

Volumn 3, Issue 2, 2015, Pages 184-195

  Rahbar, Ramtin ^a,b   Lin, Albert ^a,b   Ghazarian, Magar ^a,b   Yau, Helen Loo ^a,b   Paramathas, Sangeetha ^a,b   Lang, Philipp A ^c   Schildknecht, Anita ^a   Elford, Alisha R ^a   Garcia Batres, Carlos ^a   Martin, Bernard ^a   Berman, Hal K ^a,b,d   Leong, Wey L ^a   McCready, David R ^e   Reedijk, Michael ^a   Done, Susan J ^a,b,d   Miller, Naomi ^b,d   Youngson, Bruce ^b,d   Suh, Woong Kyung ^f   Mak, Tak W ^a,b   Ohashi, Pamela S ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GLUCOSE; V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1; GRANZYME; GZMB PROTEIN, MOUSE; HLA ANTIGEN CLASS 1; TUMOR MARKER; TUMOR PROTEIN; VTCN1 PROTEIN, HUMAN; VTCN1 PROTEIN, MOUSE;

ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BREAST CARCINOGENESIS; CANCER INHIBITION; CANCER PATIENT; CANCER PROGNOSIS; CELLS BY BODY ANATOMY; CELLULAR IMMUNITY; CHIMERA; CYTOKINE PRODUCTION; CYTOTOXICITY ASSAY; DNA SYNTHESIS; FIBROBLAST; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSFECTION; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHEMATOPOIETIC CELL; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR VOLUME; UPREGULATION; ANIMAL; BIOSYNTHESIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DEFICIENCY; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MAMMARY NEOPLASMS, EXPERIMENTAL; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; BIOMARKERS, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANZYMES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNITY, CELLULAR; INTERFERON-GAMMA; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE, TRANSGENIC; NEOPLASM PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR MICROENVIRONMENT; UP-REGULATION; V-SET DOMAIN-CONTAINING T-CELL ACTIVATION INHIBITOR 1;

EID: 84939633426     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-14-0113     Document Type: Article

References (56)

1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
2. Yi KH, Chen L. Fine tuning the immune response through B7-H3 and B7-H4. Immunol Rev 2009;229:145-51.
3. Ceeraz S, Nowak EC, Noelle RJ B7 family checkpoint regulatorsinimmune regulation and disease. Trends Immunol 2013;34:556-63.
4. Sica GL, Choi IH, Zhu G, Tamada K., Wang SD, Tamura H, et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 2003;18:849-61.
5. Zang X, Loke P, Kim J., Murphy K, Waitz R, Allison JP B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A 2003;100:10388-92.
6. Prasad DV, Richards S, Mai X.M., Dong C. B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 2003;18: 863-73.
7. Wei J, Loke P, Zang X., Allison JP. Tissue-specific expression of B7x protects from CD4 T cell-mediated autoimmunity. J Exp Med 2011;208: 1683-94.
8. Lee JS, Scandiuzzi L, Ray A., Wei J, Hofmeyer KA, Abadi Y.M., et al. B7x in the periphery abrogates pancreas-specific damage mediated by self-reactive CD8 T cells. J Immunol 2012;189:4165-74.
9. Suh WK, Wang S, Duncan G.S., Miyazaki Y., Cates E, Walker T, et al Generation and characterization of B7-H4/B7S1/B7x-deficient mice. Mol Cell Biol 2006;26:6403-11.
10. Hofmeyer KA, Scandiuzzi L, Ghosh K., Pirofski LA, Zang X. Tissue-expressed B7x affects the immune response to and outcome of lethal pulmonary infection. J Immunol 2012;189:3054-63.
11. Zhu G, Augustine MM, Azuma T, Luo L., Yao S, Anand S, et al B7-H4-deficient mice display augmented neutrophil-mediated innate immunity. Blood 2009;113:1759-67.
12. Sun Y, Wang Y, Zhao J., Gu M, Giscombe R, Lefvert A.K., et al. B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer 2006;53: 143-51.
13. Salceda S, Tang T, Kmet M., Munteanu A, Ghosh M, Macina R., et al. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp Cell Res 2005;306:128-41.
14. Cheng L, Jiang J, Gao R., Wei S, Nan F, Li S., et al. B7-H4 expression promotes tumorigenesis in ovarian cancer. Int J Gynecol Cancer 2009;19:1481-6.
15. Anderson GL, McIntosh M, Wu L., Barnett M, Goodman G, Thorpe J.D., et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst 2010;102:26-38.
16. Tringler B, Liu W, Corral L., Torkko KC, Enomoto T, Davidson S, et al B7-H4 overexpression in ovarian tumors. Gynecol Oncol 2006;100:44-52.
17. Tringler B, Zhuo S, Pilkington G., Torkko KC, Singh M, Lucia MS, et al B7-h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res 2005;11:1842-8.
18. Miyatake T, Tringler B, Liu W., Liu SH, Papkoff J, Enomoto T, et al B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration. Gynecol Oncol 2007;106:119-27.
19. Zang X, Thompson RH, Al-Ahmadie HA, Serio A.M., Reuter VE, Eastham JA, et al. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U SA 2007;104:19458-63.
20. Krambeck AE, Thompson RH, Dong H, Lohse C.M., Park ES, Kuntz SM, et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A 2006;103:10391-6.
21. Jiang J, Zhu Y, Wu C., Shen Y, Wei W, Chen L., et al. Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol Immunother 2010;59:1707-14.
22. Arigami T, Uenosono Y, Hirata M., Hagihara T, Yanagita S, Ishigami S., et al. Expression of B7-H4 in blood of patients with gastric cancer predicts tumor progression and prognosis. J Surg Oncol 2010;102:748-52.
23. Awadallah NS, Shroyer KR, Langer D.A., Torkko KC, Chen YK, Bentz JS, et al Detection of B7-H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct. Pancreas 2008;36:200-6.
24. Chen LJ, Sun J, Wu H.Y., Zhou SM, Tan Y, Tan M, et al B7-H4 expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma. Cancer Immunol Immunother 2011;60:1047-55.
25. Qian Y, Hong B, Shen L., Wu Z, Yao H, Zhang L. B7-H4 enhances oncogenicity and inhibits apoptosis in pancreatic cancer cells. Cell Tissue Res 2013;353:139-51.
26. Kryczek I, Wei S, Zou L., Zhu G, Mottram P, Xu H., et al. Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol 2006;177:40-4.
27. Kryczek I, Zou L, Rodriguez P., Zhu G, Wei S, Mottram P., et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006;203:871-81.
28. Kryczek I, Wei S, Zhu G., Myers L, Mottram P, Cheng P., et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 2007;67:8900-5.
29. Foster B, Prussin C, Liu F., Whitmire JK, Whitton JL. Detection of intracellular cytokines by flow cytometry. Curr Protoc Immunol 2007;Chapter 6: Unit 6 24.
30. Gyorffy B, Lanczky A, Eklund A.C., Denkert C., Budczies J, Li Q, et al An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treatment 2010;123:725-31.
31. Lin EY, Jones JG, Li P, Zhu L., Whitney KD, Muller WJ, et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Path 2003;163:2113-26.
32. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985;315:115-22.
33. Andres AC, Schonenberger CA, Groner B, Hennighausen L., LeMeur M, Gerlinger P. Ha-ras oncogene expression directed by a milk protein gene promoter: tissue specificity, hormonal regulation, and tumor induction in transgenic mice. Proc Natl Acad Sci U S A 1987;84:1299-303.
34. Hennighausen L. The mammary gland as a bioreactor: production of foreign proteins in milk. Protein Expr Purif 1990;1:3-8.
35. Ahmed F, Wyckoff J, Lin E.Y., Wang W., Wang Y, Hennighausen L, et al GFP expression in the mammary gland for imaging of mammary tumor cells in transgenic mice. Cancer Res 2002;62:7166-9.
36. Andrechek ER, Laing MA, Girgis-Gabardo AA, Siegel P.M., Cardiff RD, Muller WJ. Gene expression profiling of neu-induced mammary tumors from transgenic mice reveals genetic and morphological similarities to ErbB2-expressing human breast cancers. Cancer Res 2003;63: 4920-6.
37. Aldaz CM, Hu Y, Daniel R., Gaddis S, Kittrell F, Medina D. Serial analysis of gene expression in normal p53 null mammary epithelium. Oncogene 2002;21:6366-76.
38. Bouchard D, Morisset D, Bourbonnais Y., Tremblay GM. Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol 2006;7: 167-74.
39. Blattman JN, Antia R, Sourdive D.J., Wang X., Kaech SM, Murali-Krishna K, et al. Estimating the precursor frequency of naive antigen-specific CD8 T cells. J Exp Med 2002;195:657-64.
40. Ohashi PS, Oehen S, Buerki K., Pircher H, Ohashi CT, Odermatt B, et al Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991;65:305-17.
41. Oldstone MB, Nerenberg M, Southern P., Price J, Lewicki H. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 1991;65:319-31.
42. Moskophidis D, Lehmann-Grube F. The immune response of the mouse to lymphocytic choriomeningitis virus. III. Differences of numbers of cytotoxic T lymphocytes in spleens of mice of different strains. Cell Immunol 1983;77:279-89.
43. Liu J, Hamrouni A, Wolowiec D., Coiteux V, Kuliczkowski K, Hetuin D., et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007;110: 296-304.
44. Dong H, Strome SE, Salomao D.R., Tamura H., Hirano F, Flies DB, et al Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800.
45. Taube JM, Anders RA, Young G.D., Xu H., Sharma R, McMiller TL, et al Colocalizationofinflammatory response with B7-h1 expressioninhuman melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012;4:127ra37.
46. Martin-Fontecha A., Thomsen LL, Brett S, Gerard C., Lipp M, Lanzavecchia A, et al Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H) 1 priming. Nat Immunol 2004;5:1260-5.
47. Li Z, Pradera F, Kammertoens T., Li B, Liu S, Qin Z. Cross-talk between T cells and innate immune cells is crucial for IFN-gamma-dependent tumor rejection. J Immunol 2007;179:1568-76.
48. Mugler KC, Singh M, Tringler B., Torkko KC, Liu W, Papkoff J, et al B7-h4 expression in a range of breast pathology: correlation with tumor T-cell infiltration. Appl Immunohistochem Mol Morphol 2007;15: 363-70.
49. Quandt D, Fiedler E, Boettcher D., Marsch W, Seliger B. B7-h4 expression in human melanoma: its association with patients' survival and antitumor immune response. Clin Cancer Res 2011;17: 3100-11.
50. Hodi FS, O'Day SJ, McDermott DF, Weber R.W., Sosman JA, Haanen JB, et al. Improved survival with ipilimumabinpatientswithmetastatic melanoma. N Engl J Med 2010;363:711-23.
51. Thompson JA, Hamid O, Minor D., Amin A, Ron IG, Ridolfi R, et al Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial. J Immunother 2012;35:73-7.
52. Weber J, Thompson JA, Hamid O, Minor D., Amin A, Ron I, et al A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009;15:5591-8.
53. Topalian SL, Drake CG, Pardoll DM Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012;24:207-12.
54. Lyford-Pike S., Peng S, Young G.D., Taube JM, Westra WH, Akpeng B, et al Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res 2013;73:1733-41.
55. Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, et al Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
56. Wolchok JD, Kluger H, Callahan M.K., Postow MA, Rizvi NA, Lesokhin AM, et al Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33.